Evidence map›Paper›PMID 39040010›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Vaccinome Landscape in Nearly 620 000 Patients With Diabetes.

Francesca D'Addio, Elisa Lazzaroni, Maria Elena Lunati, Giuseppe Preziosi, Michele Ercolanoni, Giulio Turola, Chiara Marrocu, Giovanni Cicconi, Sudwaric Sharma, Simona Scarioni and 18 more

Abstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Francesca D'AddioDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Elisa LazzaroniDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Maria Elena LunatiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Giuseppe PreziosiARIA S.p.A. (The Innovation and Procurement Regional Company of Regione Lombardia), 20124 Milano, Lombardia, Italy.
Michele ErcolanoniARIA S.p.A. (The Innovation and Procurement Regional Company of Regione Lombardia), 20124 Milano, Lombardia, Italy.
Giulio TurolaARIA S.p.A. (The Innovation and Procurement Regional Company of Regione Lombardia), 20124 Milano, Lombardia, Italy.
Chiara MarrocuPostgraduate School in Public Health, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
Giovanni CicconiPostgraduate School in Public Health, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
Sudwaric SharmaPostgraduate School in Public Health, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
Simona ScarioniPostgraduate School in Public Health, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
Laura MontefuscoDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Ida PastoreDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Paola Silvia MorpurgoDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Antonio RossiInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Alessandra GandolfiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Camilla TinariDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Giada RossiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.
Moufida Ben NasrInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Cristian LoretelliInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Roberta Maria FiorinaInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Baldassarre GrassaU.O.S. Diabetologia ASST Lariana, P.O. Mariano Comense, CO 22066, Italy.
Rosa TerranovaDivision of Diabetology, Niguarda Hospital, 20162 Milan, Italy.
Loredana BucciarelliInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Cesare BerraIRCCS MultiMedica Sesto San Giovanni, 20099 Milano, Italy.
Danilo CeredaDirectorate General for Health, 20124 Milano, Lombardia, Italy.
Gianvincenzo ZuccottiBuzzi Children's Hospital, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, 20157 Milan, Italy.
Catia Rosanna BorrielloDirectorate General for Health, 20124 Milano, Lombardia, Italy.
Paolo FiorinaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy.ORCID 0000-0002-1093-7724

Funding

Italian Ministry of Health RF-2021-12372897Italian Ministry of University and Research 2022JY9CPItalian Ministry of University Research 20229ZA2YF
6 · The paper itself

Abstract

contextType 1 (T1D) and type 2 diabetes (T2D) are associated with an elevated incidence of infectious diseases and a higher risk of infections-related hospitalization and death.

objectiveIn this study, we delineated the "vaccinome" landscape obtained with a large immunization schedule offered by the Regional Government of Lombardy in a cohort of 618 396 patients with diabetes (T1D and T2D).

methodsBetween September 2021 and September 2022, immunization coverage for influenza, meningococcus, pneumococcus, and herpes zoster was obtained from the public computerized registry of the health care system of Lombardy Region (Italy) in 618 396 patients with diabetes and in 9 534 087 subjects without diabetes. Type of diabetes, age, mortality, and hospitalizations were retrospectively analyzed in vaccinated and unvaccinated patients.

resultsAmong patients with diabetes (T1D and T2D), 44.6% received the influenza vaccine, 10.9% the pneumococcal vaccine, 2.5% the antimeningococcus vaccine, and 0.7% the antizoster vaccine. Patients with diabetes immunized for influenza, zoster, and meningococcus showed a 2-fold overall reduction in mortality risk and a decrease in hospitalizations. A 3-fold lower risk of mortality and a decrease in hospitalizations for both cardiac and pulmonary causes were also observed after influenza, zoster, and meningococcus immunization in older patients with diabetes.

conclusionImmunization coverage is still far from the recommended targets in patients with diabetes. Despite this, influenza vaccination protected nearly 3800 per 100 000 patients with diabetes from risk of death. The overall impressive decrease in mortality and hospitalizations observed in vaccinated patients strengthens the need for scaling up the "vaccinome" landscape in patients with diabetes.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2VaccinationVaccination CoverageAdolescentAdultAgedAged, 80 and overFemaleHospitalizationHumansInfluenza VaccinesItalyMaleMeningococcal VaccinesMiddle AgedInfluenza VaccinesMeningococcal VaccinesPneumococcal Vaccinesdiabeteshospitalizationimmunization coveragemortalityvaccines

Identifiers

PMID39040010
PMCPMC12012803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.